ClinicalTrials.gg
Not yet recruitingNCT07938060SUNRISEUpdated Nov 16, 2026

Study of the BioRISE Biolimus Drug-Coated Balloon Versus the SELUTION SLR Sirolimus-Coated Balloon in De Novo Coronary Lesions, With a Single-Arm In-Stent Restenosis Cohort (SUNRISE)

An Early Phase 1 interventional study of Biolimus A9 Drug Coated Balloon and SELUTION SLR in Angina (Stable), Unstable Angina (UA) and NSTEMI, sponsored by Biosensors Europe SA. Not yet recruiting at 2 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Biosensors Europe SA (part of Blue Sail Medical Co., Ltd.) · Early Phase 1, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
443
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 47 studies in Angina, Stable with a site in United Kingdom — 9 open to participants now, 13 under way, none of them phase 3. Angina, Stable · United Kingdom.

Planned enrollment
8th of 26
443 · median 240
Started
2027
the only one that year
Phase 1
Only one
of the 47
Primary completion
2029-01
later than 9 of 12 live
Registered
47th of 47
by date
Lead sponsor
2 of 47
Biosensors Europe SA

Among the 47 studies in Angina, Stable with a site in United Kingdom, this one is the 8th largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2027, is the only one in phase 1, reaches primary completion later than 9 of the 12 other live ones, and was the 47th registered.

Angina, Stable

344 studies on the registry are indexed under Angina, Stable; 56 are open to participants now.

Browse Angina, Stable studies →

Open to participants now

9 of the 47 studies in Angina, Stable with a site in United Kingdom are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 39 Angina, Stable studies recruiting now, 33 (85%) set no upper age limit and 2 (5%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Angina, Stable with a site in United Kingdom, or all of them as a file.
02

Study summary

Coronary heart disease causes narrowing of the heart (coronary) arteries (arteries are blood vessels, which supply oxygen-rich blood to the heart muscle). Your heart specialist will have explained to you that they suspect that you have a narrowing in one or more of your heart arteries. This narrowing may be causing you to have chest pains or evidence of reduced blood supply to your heart muscle.

One commonly used treatment for this problem is to stretch the narrowing with a balloon and then insert a small mesh-like device called a stent, which will hold the artery open, improving the blood flow to your heart, and thereby help with your symptoms. An alternative treatment is to open the narrowing with a balloon that is coated with an anti-inflammatory drug (so called drug-coated balloon) as treatment instead of a stent. Drug-coated balloons are used to reduce the risk of re-narrowing of your coronary arteries without leaving an implant (like a stent) behind. A stent (which is a foreign object that does not belong in the body) can cause vessel inflammation and it bears the risk of blockage within the stent (in-stent restenosis or ISR). Drug-coated balloons leave no implant behind but target the narrowing in your vessel wall with the delivery of an anti-inflammatory agent to the vessel wall, allowing the blood vessel to heal.

Biosensors has developed a balloon coated with a drug called Biolimus A9™ which suppresses inflammation in the artery where the narrowing has occurred. We refer to this balloon coated with Biolimus A9™ as BA9-DCB (Biolimus A9™ drug-coated balloon) also known as BioRISE. This device is not commercially available and will be tested in this study for the first time in humans. However, several coronary stents made by Biosensors are already on the market that contain the Biolimus A9™ drug. It has been proven to be safe and effective in preventing re-narrowing of the artery where the stent is placed.

In this study, two types of drug-coated balloons (DCBs) will be used; the BioRISE (test group; group 1) and SELUTION SLR, a balloon that is coated with sirolimus (control group; group 2). The SELUTION SLR balloon is commercially available in Europe.

The study has the following design:

  • Patients will be treated according to standard hospital procedures using the study device.

The study has the following design:

  • Patients will be treated according to standard hospital procedures using the study device.
  • There will be two different types of patients included in this study.
  • 400 patients with a narrowing in a heart artery that has never been treated before (referred to as de novo disease), of whom 200 will be treated with the BioRISE balloon and 200 with the SELUTION SLR balloon. The allocation to the two possible treatments is random as it must be in a study like this. Of these 400 patients, 15 in each treatment arm, will have the inside of the artery imaged during the procedure using a well-established technique called Optical Coherence Tomography (OCT) and Quantitative Flow Ratio (QFR)
  • 43 patients with a narrowing inside a stent that was implanted in the past (referred to as in-stent restenosis). In these patients, only the BioRISE balloon will be used.
  • Your doctor will explain to which category applies to you.
  • There will be up to 25 hospitals taking part in the study in the UK, and in up to 5 European countries
  • Patients will be taking part in the study for up to 3 years, and during this time their health status will be assessed by telephone or hospital visit at 1month, 9 month, 12 months, 24 months and 36 months.
  • There will be a check up angiography to assess the primary end point at 9 months for all participants.
Read the detailed description

Devices used :

Investigational device: BioRISE Biolimus Drug-Coated Balloon. Comparator: SELUTION SLR sirolimus-coated balloon (de novo randomised cohort only).

Purpose and Background:

Coronary drug-coated balloons provide an anti-restenotic effect without a permanent implant. This study evaluates the BioRISE Biolimus Drug-Coated Balloon against an established sirolimus drug-eluting balloon (SELUTION SLR) in de novo coronary lesions, with a supportive single-arm cohort in in-stent restenosis, to generate clinical evidence supporting CE marking under Regulation (EU) 2017/745 (MDR).

Clinical Development stage:

Pre-Market Phase (Interventional) - Pivotal clinical investigation.

Study population:

Patients with de novo coronary artery lesions (randomised cohort) and with in-stent restenosis (single-arm cohort).

Total 443 subjects: 400 randomised de novo (200 BioRISE : 200 SELUTION SLR) plus 43 ISR (BioRISE only), at up to 25 sites in up to 6 European countries.

Design:

Prospective, randomised (1:1), multicentre, single-blind (with blinded angiographic core laboratory and blinded independent CEC adjudication study with an additional single-arm ISR safety cohort.

Objectives:

Demonstrate non-inferiority of BioRISE versus SELUTION SLR for in-segment LLL at 9 months in de novo coronary lesions.

Primary endpoints:

In-segment Late Lumen Loss (LLL) (or Gain) at 9 months Defined as the difference between post-procedural minimal lumen diameter (MLD) and 9-month follow-up MLD, measured by quantitative coronary angiography (QCA), assessed by a blinded angiographic core laboratory.

Analysis segment: in-segment, defined for this study as the balloon-treated segment plus 5 mm proximal and 5 mm distal, consistent with the comparator's pivotal trials (SELUTION DeNovo). ARC-DCB defines in-segment as the treated segment plus 1 mm, the ARC-DCB rationale for in-segment analysis (a proximal and distal buffer zone mitigating geographic miss= applies equally. The core laboratory additionally reports in-segment LLL with the ARC-DCB 1 mm margins.

Primary Endpoint Justification:

Per ARC-DCB, LLL is expected to be reliable when comparing different types of DCBs (DCB vs DCB).

Clinical secondary endpoints

  • Clinical secondary endpoints Device-Oriented Composite Endpoint (DOCE; ARC-DCB) at all timepoints: hierarchical occurrence of cardiovascular death, device-failure-related MI (not clearly attributable to a non-target vessel), device-failure-related ischaemia, and clinically driven target lesion revascularisation (TLR).

Lesion-Oriented Composite Endpoint (LOCE; ARC-DCB) at 30 days: definite lesion thrombosis, clinically driven TLR, and device-failure-related MI (not clearly attributable to a non-target vessel).

Target Lesion Failure (TLF; ARC-DCB) at all timepoints: composite of cardiovascular death, target-vessel MI, and clinically driven TLR.

Target Vessel Failure (TVF; ARC-DCB) at all timepoints: cardiovascular death, target-vessel MI, and clinically driven target vessel revascularisation.

Target-vessel MI (ARC-DCB) at all timepoints. All-cause mortality and cardiovascular death (per ARC-2 as adopted by ARC-DCB). Any myocardial infarction (Fourth and Fifth Universal Definition of Myocardial Infarction).

Peri-procedural myocardial infarction (ARC-DCB) at discharge and 30 days. Any stroke (ischaemic, haemorrhagic or undetermined; Neuro-ARC) at all timepoints

Any definite lesion thrombosis (ARC-DCB [20]): angiographic confirmation of thrombus originating in, or within 5 mm of, the treated segment, or pathological (autopsy) confirmation, in the presence of an acute ischaemic clinical syndrome. Classified by timing as acute (≤ 24 h), subacute (> 24 h-30 days), late (> 30 days-1 year) and very late (> 1 year).

All TLR, TVR and non-TVR (ARC-DCB) at all timepoints. BARC 3-5 bleeding (BARC [34], as adopted by ARC-DCB) at discharge, 30 days and 1 year

  • Angiographic and physiological secondary endpoints (9 months)

Binary restenosis (> 50% diameter stenosis in the target segment at follow-up by QCA; ARC-DCB).

  • Procedural endpoints (per ARC-DCB)

Device success (ARC-DCB): successful delivery in time and inflation within 30-60 s of the allocated DCB device at the intended target lesion during an attempt with a DCB not previously used (first use), successful withdrawal of the device system, and attainment of a final in-segment residual stenosis of \<40% with final data reported by core laboratory QCA.

Procedural success (ARC-DCB): device success and freedom from in-hospital cardiovascular death, TLR, peri-procedural MI, any stroke and BARC 3-5 bleeding.

OCT substudy:

Pre-specified OCT sub-study at participating sites (de novo cohort only) in UK, restricted to subjects whose target lesion has a reference vessel diameter (RVD) ≥ 3.0 mm by visual estimation. In 30 subjects (15 per randomised arm), OCT of the target lesion is acquired at two time points: after lesion preparation (before randomisation and DCB application) and at the 9-month angiographic follow-up and analysed at 1 mm intervals of the treated segment by the OCT core laboratory (CERC).

The primary OCT outcome measure is the percentage change in minimal lumen area from post-lesion preparation to 9 months, compared between BioRISE and SELUTION SLR in 15 subjects per randomised arm (30% lumen-area reduction assumed in both arms, 50% non-inferiority limit, α = 5%, 90% power).

Additional variables include plaque characterisation and dissection after lesion preparation, plaque healing/layering at 9 months and treated-segment lumen volume.

Sub-study analyses are exploratory and do not contribute to the confirmatory analysis of the primary endpoint.

Randomization:

1:1 (BioRISE : SELUTION SLR) via a central, validated electronic randomisation system in the EDC, with concealed allocation, using randomly permuted blocks of variable size, stratified by site. Randomisation is performed after successful lesion preparation (Inclusion Criterion 15) and immediately before device application. The single-arm ISR cohort is not randomised.

Study oversight:

An independent DSMB reviews safety data at pre-specified intervals per the DSMB Charter. An independent Clinical Events Committee (CEC) adjudicates deaths, MI, stroke, lesion thrombosis and revascularisations.

An angiographic core laboratory (CERC) performs QCA/QFR. The study is monitored per a monitoring plan, with data captured in a validated electronic data capture (EDC) system.

Follow-up:

Discharge; 30 days (± 7 days); 9 months (± 30 days, with protocol-mandated coronary angiography - primary endpoint); and 1, 2 and 3 years (± 30 days). Visits are performed in clinic as specified in the follow-up schedule.

Study duration:

Approximately 12 months enrollment; each subject is followed for approximately 3 years. The primary-endpoint analysis is performed after all subjects complete the 9-month angiographic follow-up.

Statistical considerations:

De novo cohort:

Non-inferiority of BioRISE versus SELUTION SLR on in-segment LLL at 9 months. With a margin Δ = 0.19 mm, common SD 0.50 mm, at least 90% power and α = 5% two-sided (2.5% one-sided), 178 evaluable subjects per arm are required; allowing for 11% drop-out, 400 subjects are randomised (200 : 200).

Primary analysis per-protocol with supplementary ITT; non-inferiority is concluded if the upper bound of the two-sided 95% CI for the mean LLL difference (BioRISE - SELUTION SLR) is \< 0.19 mm.

If met, superiority is subsequently tested.

ISR cohort:

Single-arm, descriptive; in-segment LLL at 9 months against a performance goal of 0.497 mm (sirolimus arm of SIBLINT and Biolimus arm of BIO-ASCEND ISR; weighted late loss 0.297 mm, weighted SD 0.427 mm). With a margin Δ = 0.2 mm, 80% power and α = 2.5% one-sided, 38 evaluable subjects are required; allowing for 10% drop-out, 43 are enrolled.

Total study enrollment: 443 subjects.

OCT sub-study (de novo cohort): percentage change in MLA from post-lesion preparation to 9 months, 30% expected in both arms, 50% non-inferiority limit, 90% power: 15 subjects per randomised arm (30 in total).

GCP statement and ISO:14155: 2026 This study will be conducted in compliance with the protocol, the current version of the Declaration of Helsinki, ISO 14155:2026 as well as all national legal, MDR and regulatory requirements.

03

Conditions studied

  • Angina (Stable)
  • Unstable Angina (UA)
  • NSTEMI

Keywords

  • BioRISE
  • Drug coated balloon
  • Randomized
  • SELUTION SLR
  • BioRISE versus SELUTION SLR for in-segment LLL at 9 months in de novo coronary lesions.
  • Biosensors Europe SA
  • Single arm cohort in-stent restenosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • General (all patients):

Age ≥ 18 years

Exclusion Criteria:

  • General (all patients):

    1. Age ≥ 18 years
    2. Documented angina and/or a positive functional ischaemia test, unstable angina, or a stabilized NSTEMI presentation. Patients undergoing index PCI of a non-culprit lesion after AMI may be included in the absence of further documented ischaemia/angina.
    3. Female subjects of have a negative pregnancy test ≤ 7 days before the procedure or are using a device or drug.
    4. Eligible for and willing to comply with dual antiplatelet therapy (DAPT).
    5. > 1 year.
    6. Written obtained from the subject
    7. Willing to comply with all protocol-required follow-up visits, including the 9-month angiographic follow-up.
    8. One or more target vessel (LAD, LCx or RCA) is considered to require intervention and is suitable for treatment with a drug-coated balloon.
    9. Able to tolerate 60 seconds of coronary occlusion for each target lesion.
    10. Reference vessel diameter (RVD) ≥ 1.50 mm and ≤ 4.00 mm by visual estimation.
    11. All target lesions: baseline diameter stenosis > 50% and \< 100% with distal flow of at least TIMI 2. For angiographically intermediate lesions where the indication for PCI is uncertain, lesion-specific evidence of ischaemia is demonstrated by an accepted physiological assessment (e.g. FFR, iFR or validated angiography-derived physiology) at baseline.

      De Novo Cohort (Randomised):

    12. A single de novo target lesion
    13. Target lesion length ≤ 36 mm by visual estimation.
    14. In the operator's judgement, the likelihood of requiring provisional/bail-out stenting is \< 30% for each randomised target lesion.
    15. Successful lesion predilatation/preparation prior to study DCB delivery: TIMI 3 flow, residual diameter stenosis \< 30%, and no flow-limiting or vessel-threatening dissection requiring further treatment or bail-out stenting.

      ISR Cohort (Single-Arm, BioRISE only):

    16. Prior drug-eluting stent (DES) implantation with documented in-stent restenosis (≥ 50% diameter stenosis).
    17. ISR within a single stent layer is permitted. A focal region containing two overlapping stent layers is permitted. ISR involving three or more stent layers is not allowed.
    18. ISR occurring ≥ 1 month after the original stent implantation.
    19. Successful predilatation/preparation: TIMI 3 flow, residual diameter stenosis \< 30%
    20. No acute myocardial infarction within 72 hours of the index procedure (per ARC-DCB ISR definition).

Exclusion criteria:

General all patients:

  1. Presentation with STEMI.
  2. Presentation with NSTEMI with ongoing chest pain or haemodynamic instability.
  3. Killip class III (pulmonary oedema) or IV (cardiogenic shock) at presentation.
  4. Chronic class III or IV heart failure prior to index PCI.
  5. Known \< 30% prior to index PCI.
  6. Known allergy or to Biolimus, sirolimus or other limus analogues or to the coating , to required antiplatelet/anticoagulant therapy, or to contrast media that cannot be adequately pre-medicated.
  7. Study target lesion located in the left main stem or in any arterial or venous bypass graft.
  8. Renal insufficiency (serum creatinine ≥ 2.0 mg/dL) or dialysis.
  9. Planned major surgery within one month following the index procedure.
  10. Pregnant, breast-feeding, or planning pregnancy during the study period.
  11. Definite or suspected clinically manifest active systemic infection (including clinically manifest COVID-19) at the time of the index procedure.
  12. Currently participating in another device or drug study including PMCFs.
  13. Subject is unable to comply fully with the study protocol.
  14. Subject is under judicial protection, tutorship or curatorship (France only, if selected).

    De Novo Cohort (Randomised) - additional:

  15. Chronic total occlusion (CTO; TIMI flow 0) of a study target lesion.
  16. Any previous PCI (stenting or balloon angioplasty) of the study target vessel, including in-stent restenosis at the target site (such ISR lesions may be eligible for the single-arm ISR cohort).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
443 participants (estimated)

Study arms

  • Experimental
    BioRISE Biolimus Drug-Coated Balloon

    BioRISE is a semi-compliant, rapid-exchange (RX) percutaneous transluminal coronary angioplasty (PTCA) balloon catheter built on the CE-marked RISE™ SC catheter platform with modified hypotube, compatible with a 0.014" guidewire. The device leaves no permanent implant, the only residual is the transferred drug.

    Device: Biolimus A9 Drug Coated Balloon

  • Active comparator
    SELUTION SLR sirolimus-coated balloon

    SELUTION SLR (Cordis / MedAlliance), a sirolimus-coated drug-coated balloon on a 0.014" rapid-exchange PTCA platform, CE-marked and used within its approved intended purpose.

    Device: SELUTION SLR

Interventions

  • DeviceBiolimus A9 Drug Coated Balloon

    Interventions in BioRISE arm aim to improve coronary luminal diameter for the treatment of de novo lesions well as lesions resulting from In-Stent Restenosis

  • DeviceSELUTION SLR

    The comparator applies to the de novo randomised cohort only; the single-arm ISR cohort has no comparator.

06

What researchers measure

Primary outcomes

  1. In-segment Late Lumen Loss (LLL) at 9 months

    The primary endpoint is in-segment late lumen loss at 9 months, defined as the difference between the post-procedural minimal lumen diameter (MLD) and the 9-month follow-up MLD, measured by quantitative coronary angiography (QCA) and assessed by an blinded angiographic core laboratory (ARC-DCB Table 1, item 8). Analysis segment: in-segment, defined for this study as the balloon-treated segment plus 5 mm proximal and 5 mm distal, consistent with the comparator's pivotal trials (SELUTION DeNovo). ARC-DCB defines in-segment as the treated segment plus 1 mm, the ARC-DCB rationale for in-segment analysis (a proximal and distal buffer zone mitigating geographic miss= applies equally. The core laboratory additionally reports in-segment LLL with the ARC-DCB 1 mm margins.

    Time frame: 9 months

Secondary outcomes

  1. Secondary outcomes

    Device-Oriented Composite Endpoint (DOCE) at all time points Lesion-Oriented Composite Endpoint (LOCE) at 30 days Target Lesion Failure (TLF) at all timepoints Target Vessel Failure (TVF) at all timepoints Target-vessel MI (ARC-DCB) at all timepoints. All-cause mortality and cardiovascular death (per ARC-2 as adopted by ARC-DCB). Any myocardial infarction (Fourth and Fifth Universal Definition of Myocardial Infarction). Peri-procedural myocardial infarction (ARC-DCB) at discharge and 30 days. Any stroke (ischaemic, haemorrhagic or undetermined; Neuro-ARC) at all timepoints. Any defined lesion thrombosis. All TLR, TVR and non-TVR (ARC-DCB) at all timepoints. BARC 3-5 bleeding (BARC \[34\], as adopted by ARC-DCB) at discharge, 30 days and 1 year Binary restenosis (\> 50% diameter stenosis in the target segment at follow-up by QCA; ARC-DCB). Device success Procedural success

    Time frame: • index procedure • Discharge up to 7 days (patient and hospital practice dependent) • 30 days • 9 months • 1 year • 2 years • 3 years

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2027; primary completion for Jan 2029, 22 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2026
First posted
Nov 16, 2026
StartEst.
Mar 1, 2027
Primary completionEst.
Jan 31, 2029
CompletionEst.
Mar 31, 2031
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938060
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Mar 1, 2027 (estimated)
Primary completion
Jan 31, 2029 (estimated)
Completion
Mar 31, 2031 (estimated)
Last update
Nov 16, 2026

Study contacts

Anders Jönsson
Contact
a.jonsson@biosensors.com
0041218048000
Diana Schuette
Contact
d.schuette@biosensors.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion